News

July 16, 2018July 16, 2018

XaTek Raises $9M to Advance ClotChip, Portable Device That Quickly Analyzes Blood’s Ability to Clot

News

XaTek announced that it has raised $9.1 million to advance the development of ClotChip — a portable test designed to rapidly analyze, using a single drop of blood, the ability ... Read more

July 13, 2018July 13, 2018

Companies Collaborating to Conduct Musical Workshop for Teens Affected by Bleeding Disorders

News

BioMarin Pharmaceutical Inc. is partnering with digital content agency Believe Limited to produce a three-day musical workshop for young members of the bleeding disorders community. The “Breaking Through!” musical theater intensive, ... Read more

July 11, 2018July 11, 2018

Experts Define Recommendations for Best Surgery Management Practices in Hemophilia Patients

News

A panel of multidisciplinary experts have developed recommendations for applying best practice guidelines in the planning and managing of surgery in hemophilia patients. The guidelines were outlined in the ... Read more

July 9, 2018July 9, 2018

Despite Protective Effects, Cardiovascular Disease Still a Risk in Moderate to Severe Hemophilia Patients, Study Finds

News

Although moderate to severe hemophilia patients are generally protected against the development of cardiovascular disease, cardiovascular-related events can still occur in this patient population, a study reports. These findings ... Read more

July 6, 2018July 6, 2018

Hemophilia Drug Development Summit Takes Aim at Hurdles Facing New and Upcoming Treatments

News

Key leaders in hemophilia therapy development, representing large pharmaceutical and biotech firms as well as academia and contract research organizations, will gather at the Hemophilia Drug Development conference in ... Read more

July 2, 2018July 2, 2018

First Patient Enrolled in Phase 3 Trial of uniQure’s AMT-061 for Hemophilia B

News

UniQure has enrolled the first patient in its Phase 3 HOPE-B single-dose trial investigating the effectiveness and safety of AMT-061 in treating people with severe or moderately severe hemophilia B. AMT-061 uses ... Read more

June 29, 2018June 29, 2018

Canadian PREVAIL Trial Investigates Use of Wilate for Certain Hemophilia A Patients

News

Octapharma announced the launch of the PREVAIL clinical study (NCT03344003), which will investigate the use of Wilate for treatment of hemophilia A patients in Canada who recently have developed ... Read more

June 27, 2018June 27, 2018

CB 2679d Brings Clotting Protein Levels Closer to Normal in Hemophilia B Patients, Phase 1/2 Data Show

News

Treatment with CB 2679d increased factor IX activity levels in the blood, bringing them closer to normal levels in the newest group of patients with severe hemophilia B in the Phase 1/2 ... Read more

June 25, 2018June 25, 2018

Oxidation of FVIII Increases Immune Response in Hemophilia A Mouse Model, Study Finds

News

Oxidation of clotting protein factor VIII (FVIII) increased the immune response to the replacement therapy in a mouse model of severe hemophilia A, a study found. Conducted by researchers ... Read more

June 22, 2018June 22, 2018

Developing Inhibitors Inflates Treatment Costs and Impairs Quality of Life, Study Finds

News

Hemophilia patients who develop inhibitors against treatment face markedly higher healthcare costs — about three times those of other patients — and experience poorer quality of life, according to a ... Read more

Pin It on Pinterest